Molecular profiling of appendiceal epithelial tumors using massively parallel sequencing to identify somatic mutations

Clinical Chemistry

Volumn 60, Issue 7, 2014, Pages 1004-1011

  Liu, Xiaoying ^a   Mody, Kabir ^b   De Abreu, Francine B ^a   Pipas, J Marc ^b   Peterson, Jason D ^a   Gallagher, Torrey L ^a   Suriawinata, Arief A ^a   Ripple, Gregory H ^b   Hourdequin, Kathryn C ^b   Smith, Kerrington D ^b   Barth Jr , Richard J ^b   Colacchio, Thomas A ^b   Tsapakos, Michael J ^b   Zaki, Bassem I ^b   Gardner, Timothy B ^b   Gordon, Stuart R ^b   Amos, Christopher I ^c,d   Wells, Wendy A ^a   Tsongalis, Gregory J ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b Department of Medicine Section of Hematology/Oncology ^*  (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d NORRIS COTTON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; JANUS KINASE 3; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN KINASE LKB1; PROTEIN P53;

APPENDIX TUMOR; ARTICLE; COLON POLYPOSIS; CONTROLLED STUDY; EPITHELIUM TUMOR; GENE MUTATION; GOBLET CELL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MET PROTO ONCOGENE; MUCOCELE; NEUROBLASTOMA; ONCOGENE; PERITONEUM PSEUDOMYXOMA; PROTO ONCOGENE; RETINOBLASTOMA; SOMATIC MUTATION; THYMOMA; TUMOR GENE; VIRUS ONCOGENE;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; APPENDICEAL NEOPLASMS; CARCINOID TUMOR; CARCINOMA, SIGNET RING CELL; GENE EXPRESSION PROFILING; HUMANS; MUCOCELE; MUTATION; PERITONEAL NEOPLASMS; PSEUDOMYXOMA PERITONEI; SEQUENCE ANALYSIS, DNA;

EID: 84903707574     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2014.225565     Document Type: Article

References (19)

1. Connor SJ, Hanna GB, Frizelle FA. Retrospective clinicopathologic analysis of appendiceal tumors from 7, 970 appendectomies. Dis Colon Rectum 1998;41:75-80.
2. Turaga KK, Pappas SG, Gamblin T. Importance of histologic subtype in the staging of appendiceal tumors. Ann Surg Oncol 2012;19:1379-85.
3. Tsongalis GJ, Peterson JD, de Abreu FB, Tunkey CD, Gallagher TL, Strausbaugh LD, et al. Routine use of the Ion Torrent AmpliSeqTM Cancer Hotspot Panel for identification of clinically actionable somatic mutations. Clin Chem Lab Med 2014;52:707-14.
4. McGory ML, Maggard MA, Kang H, O'Connell JB, Ko CY. Malignancies of the appendix: beyond case series reports. Dis Colon Rectum 2005;48:2264-71.
5. Kabbani W, Houlihan PS, Luthra R, Hamilton SR, Rashid A. Mucinous and nonmucinous appendiceal adenocarcinomas: different clinicopathological features but similar genetic alterations. Mod Pathol 2002;15:599-605.
6. Tabernero J, Van Cutsem E, Diaz-Rubio E, Cervantes A, Humblet Y, Andre T, et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007;25:5225-32.
7. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
8. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
9. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-9.
10. Patel GS, Karapetis CS. Personalized treatment for advanced colorectal cancer: KRAS and beyond. Cancer Manag Res 2013;5:387-400.
11. Dimmler A, Geddert H, Faller G. EGFR, KRAS, BRAF-mutations and microsatellite instability are absent in goblet cell carcinoids of the appendix. Pathol Res Pract 2014;210:274-8.
12. Cuatrecasas M, Matias-Guiu X, Prat J. Synchronous mucinous tumors of the appendix and the ovary associated with pseudomyxoma peritonei. A clinicopathologic study of six cases with comparative analysis of c-Ki-ras mutations. Am J Surg Pathol 1996;20:739-46.
13. Bazan V, Migliavacca M, Zanna I, Tuiolo C, Grassi N, Latteri MA, et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 2002;13:1438-46.
14. Zauber P, Berman E, Marotta S, Sabbath-Solitare M, Bishop T. Ki-ras gene mutations are invariably present in low-grade mucinous tumors of the vermiform appendix. Scan J Gastroenterol 2011;46:869-74.
15. Shetty S, Thomas P, Ramanan B, Sharma P, Govindarajan V, Loggie B. Kras mutations and p53 overexpression in psedomyxoma peritonei: association with phenotype and prognosis. J Surg Res 2013;180:97-103.
16. Nishikawa G, Sekine S, Ogawa R, Matsubara A, Mori T, Taniguchi H, et al. Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms. Br J Cancer 2013;108:951-8.
17. Ramnani DM, Wistuba II, Behrens C, Gazdar AF, Sobin LH, Albores-Saavedra J. K-ras and p53 mutations in the pathogenesis of classical and goblet cell carcinoids of the appendix. Cancer 1999;86:14-21.
18. Stancu M, Tsung-Teh W, Wallace C, Houlihan PS, Hamilton SR, Rashid A. Genetic alterations in goblet cell carcinoids of the vermiform appendix and comparison with gastrointestinal carcinoid tumors. Mod Pathol 2003;16:1189-98.
19. Fleming NI, Jorissen RN, Mouradov D, Christie M, Sakthianandeswaren A, Palmieri M, et al. SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer Res 2013;73:725-35.